Promising data for treatment of age-related macular degeneration

Data presented at the 14th EURETINA congress in London, highlight that treatment with EYLEA® (aflibercept solution for injection) for the treatment of wet age-related macular degeneration (wAMD) in the real-life setting has resulted in improved visual and /or anatomical outcomes in treatment-naïve and pre-treated patients. Commenting on the data, Luis-Felipe Graterol, Medical Director, Bayer HealthCare said, ‘It is encouraging to see that the efficacy seen in the clinical trials for Eylea is being reflected in clinical practice and that patients are benefitting from this treatment across the country. The continued enthusiasm to investigate Eylea’s use in the clinical setting will work towards